Literature DB >> 26862063

Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?

Endalkachew A Alamneh1, Leanne Chalmers2, Luke R Bereznicki2.   

Abstract

BACKGROUND AND OBJECTIVES: Atrial fibrillation (AF) and the associated risk of stroke are emerging epidemics throughout the world. Suboptimal use of oral anticoagulants for stroke prevention has been widely reported from observational studies. In recent years, direct oral anticoagulants (DOACs) have been introduced for thromboprophylaxis. We conducted a systematic literature review to evaluate current practices of anticoagulation in AF, pharmacologic features and adoption patterns of DOACs, their impacts on proportion of eligible patients with AF who receive oral anticoagulants, persisting challenges and future prospects for optimal anticoagulation. LITERATURE SOURCE AND SELECTION CRITERIA: In conducting this review, we considered the results of relevant prospective and retrospective observational studies from real-world practice settings. PubMed (MEDLINE), Scopus (RIS), Google Scholar, EMBASE and Web of Science were used to source relevant literature. There were no date limitations, while language was limited to English. Selection was limited to articles from peer reviewed journals and related to our topic.
RESULTS: Most studies identified in this review indicated suboptimal use of anticoagulants is a persisting challenge despite the availability of DOACs. Underuse of oral anticoagulants is apparent particularly in patients with a high risk of stroke. DOAC adoption trends are quite variable, with slow integration into clinical practice reported in most countries; there has been limited impact to date on prescribing practice.
CONCLUSION: Available data from clinical practice suggest that suboptimal oral anticoagulant use in patients with AF and poor compliance with guidelines still remain commonplace despite transition to a new era of anticoagulation featuring DOACs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26862063     DOI: 10.1007/s40256-016-0161-8

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.571


  24 in total

Review 1.  Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age.

Authors:  Leo F Buckley; Eva Rybak; Ahmed Aldemerdash; Judy W M Cheng; John Fanikos
Journal:  Clin Cardiol       Date:  2016-10-07       Impact factor: 2.882

2.  Procedural success and intra-hospital outcome related to left atrial appendage morphology in patients that receive an interventional left atrial appendage closure.

Authors:  Christian Fastner; Michael Behnes; Benjamin Sartorius; Annika Wenke; Ibrahim El-Battrawy; Uzair Ansari; Ishar-Singh Gill; Martin Borggrefe; Ibrahim Akin
Journal:  Clin Cardiol       Date:  2017-04-13       Impact factor: 2.882

Review 3.  Cardiovascular Pharmacotherapies Focus: Are low doses of direct-acting oral anticoagulants justified and appropriate in patients with nonvalvular atrial fibrillation?

Authors:  Antoni Martínez-Rubio; Gheorghe-Andrei Dan
Journal:  Eur Cardiol       Date:  2016-12

Review 4.  Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present).

Authors:  Rami A Al-Horani
Journal:  Expert Opin Ther Pat       Date:  2019-12-19       Impact factor: 6.674

Review 5.  Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review.

Authors:  Joana Santos; Natália António; Marília Rocha; Ana Fortuna
Journal:  Br J Clin Pharmacol       Date:  2020-02-05       Impact factor: 4.335

6.  Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: insights from a large German claims database.

Authors:  Stefan H Hohnloser; Edin Basic; Michael Nabauer
Journal:  Clin Res Cardiol       Date:  2019-02-15       Impact factor: 5.460

7.  Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study.

Authors:  Endalkachew Admassie; Leanne Chalmers; Luke R Bereznicki
Journal:  Eur J Clin Pharmacol       Date:  2017-09-22       Impact factor: 2.953

8.  Sulfonated non-saccharide molecules and human factor XIa: Enzyme inhibition and computational studies.

Authors:  Rami A Al-Horani; Elnaz Parsaeian; Mariam Mohammad; Madhusoodanan Mottamal
Journal:  Chem Biol Drug Des       Date:  2022-04-11       Impact factor: 2.873

9.  Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation.

Authors:  Inmaculada Hernandez; Meiqi He; Maria M Brooks; Samir Saba; Walid F Gellad
Journal:  Am J Cardiovasc Drugs       Date:  2020-04       Impact factor: 3.571

10.  Anticoagulant Utilization and Direct Oral Anticoagulant Prescribing in Patients with Nonvalvular Atrial Fibrillation.

Authors:  Priscilla Shum; Gordon Klammer; Dale Toews; Arden Barry
Journal:  Can J Hosp Pharm       Date:  2019-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.